Table 1.
Signaling pathway involved in influence of MDSCs in liver cancer
| Signaling pathway | Role | Intervention way | References |
|---|---|---|---|
| AKT/STAT3/ERK | Upregulate in MDSC accumulation and expansion | Gansui-Banxia Decoction | [85] |
| GM-CSF/JAK2/STAT3 | Expression GM-CSF, IDO and PD-L1 in L-MDSC |
STAT3 inhibition JAK2 inhibition |
[86] |
| HIF/ENTPD2/CD39L1 | Block the differentiation and maintenance of MDSCs | ENTPD2 inhibition | [88] |
| αKG/HIF1α/CSF-1 | Recruit TAMs and MDSCs accumulation | CSF1R inhibitor | [90] |
| NF-κB | Secretion IL-1α, IL-1β, and IL-6 cytokines and recruitment MDSCs and Treg | – | [93] |
| 5-LO/LTB4/BLT2 | Hyperactivated 5-LO metabolism in CD33+ MDSCs | – | [99] |
| TLR4/CXCL1/CXCR2 | Accumulation of CXCR2 + PMN-MDSCs | Neomycin | [101] |
| CXCL10/TLR4/MMP14 | Mobilized and recruited M-MDSC | – | [106] |
| p38 MAPK | Induces M-MDSC accumulation and immunosuppression function |
i-BET762 PD-L1 |
[110] |
| Mettl1/TGF-β2/PMN-MDSC | Up-regulate PMN-MDSCs and reduced CD8+ T cells | Anti-Ly6G antibody, knockdown of Mettl1 or Tgfb2 blockade TGF-β signaling | [109] |